Eli Lilly in Charts: Mounjaro and Zepbound continue to fuel blockbuster growth in Q2
Covered by 2 sources · 2 articles
2 outlets - including Invezz and Seekingalpha - are covering this story. Eli Lilly stock LLY gained 6% on Wednesday after delivering a stronger-than-expected second quarter as robust demand for its blockbuster GLP-1 medicines Mounjaro and Zepbound lifted revenue and profit well above Wall Street expectations. Th…
All coverage
Eli Lilly stock surges 6% after Q2 earnings beat driven by Mounjaro, Zepbound
Eli Lilly stock LLY gained 6% on Wednesday after delivering a stronger-than-expected second quarter as robust demand for its blockbuster GLP-1 medicines Mounjaro and Zepbound lifted revenue and profit well above Wall Street expectations. Th…
Eli Lilly in Charts: Mounjaro and Zepbound continue to fuel blockbuster growth in Q2